However, complete response rates with single-agent BTK inhibitors in Waldenström’s Macroglobulinemia are low suggesting that alternative survival signaling pathways in WM cells remain activated in patients treated with BTK inhibitors (33). The gene discussed is BTK; the disease is Waldenstrom macroglobulinemia.